ESCMID: Management of COVID-19 in immunocompromised patients: an European Society of Clinical Microbiology and Infectious Diseases consensus document

Zusammenfassung

Management of COVID-19 in immunocompromised patients: an European Society of Clinical Microbiology and Infectious Diseases consensus document Abstract Introduction: Data on treatment of COVID-19 in immunocompromised patients emerged recently; however, published guidelines for the management of COVID-19 in immunocompromised patients are lacking. Aim and methods: To develop consensus statements derived from evidence and expert opinion on management of COVID-19 in immunocompromised patients, an exp

Kerninformationen

ch question, systematic literature searches were undertaken. We considered most study types, including clinical trials, observational studies with or without a control group, systematic reviews, case series, and case reports. Detailed inclusion criteria were defined for each research question using ...

ear of COVID-19 diagnosis; (f) receipt of systemic corticosteroid therapy with a dose of ≥20 mg prednisone or equivalent daily for ≥14 days or a cumulative dose of >600 mg of prednisone; (g) receipt of biological immune modulators; or (h) receipt of disease-modifying antirheumatic drugs or other imm...

d. Publication types Consensus Statement MeSH terms COVID-19 Drug Treatment COVID-19* / therapy Europe Humans Immunocompromised Host* Immunosuppressive Agents / therapeutic use Substances Immunosuppressive Agents

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen